Framycetin

• Catalog No.: DB00452
• CAS Number: 119-04-0
• M. F.: C23H46N6O13
• M. W.: 614.64374

SYNONYMS

• IUPAC name: (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
• IUPAC Traditional name: (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2R,3S,4R,6S)-4,6-diamino-2-{[(2S,3R,4S,5R)-4-{[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy}-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy}-3-hydroxycyclohexyl]oxy}oxane-3,4-diol
• Brand Name: Actiline; Soframycine; Neomycin A; Soframycin Ophthalmic; Soframycin; Actilin; Antibiotique; Enterfram; Fradiomycin B; Framygen; Nebramycin X; Negamicin; Dekamycin V
• Synonyms: Framycetinum [INN-Latin]; Neomycin B; Streptothricin B

DATABASE IDS

• PubChem SID: 46508892
• PubChem CID: 8378
• CAS Number: 119-04-0

PROPERTIES

• Hydrophobicity(logP): -7.8

DETAILS

Description (English)

• Drug Groups: approved
• Description: A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed)
• Indication: For the treatment of bacterial blepharitis, bacterial bonjunctivitis, corneal injuries, corneal ulcers and meibomianitis. For the prophylaxis of ocular infections following foreign body removal
• Pharmacology: Framycetin is used for the treatment of bacterial eye infections such as conjunctivitis. Framycetin is an antibiotic. It is not active against fungi, viruses and most kinds of anaerobic bacteria. Framycetin works by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Framycetin is useful primarily in infections involving aerobic bacteria bacteria.
• Affected Organisms: Enteric bacteria and other eubacteria
• External Links: Wikipedia